Gisèle Clofent-Sanchez

MRI of inducible P‐selectin expression in human activated platelets involved in the early stages of atherosclerosis

The noninvasive imaging of atherosclerotic plaques at an early stage of atherogenesis remains a major challenge for the evaluation of the pathologic state of patients at high risk of acute coronary syndromes. Recent studies have emphasized the importance of platelet–endothelial cell interactions in atherosclerosis‐prone arteries at early stages, and the prominent role of P‐selectin in the initial loose contact between platelets and diseased vessel walls. A specific MR contrast agent was developed here for the targeting, with high affinity, of P‐selectin expressed in large amounts on activated platelets and endothelial cells. For this purpose, PEGylated dextran/iron oxide nanoparticles [PEG, poly(ethylene glycol)], named versatile ultrasmall superparamagnetic iron oxide (VUSPIO) particles, labeled with rhodamine were coupled to an anti‐human P‐selectin antibody (VH10). Flow cytometry and microscopy experiments on human activated platelets were highly correlated with MRI (performed at 4.7 and 0.2 T), with a 50% signal decrease in T2 and T1 values corresponding to the strong labeling of activated vs resting platelets. The number of 1000 VH10–VUSPIO nanoparticles attained per activated platelet appeared to be optimal for the detection of hypo‐ and hyper‐signals in the platelet pellet on T2‐ and T1‐weighted MRI. Furthermore, in vivo imaging of atherosclerotic plaques in ApoE mice at 4.7 T showed a spatial resolution adapted to the imaging of intimal thickening and a hypo‐signal at 4.7 T, as a result of the accumulation of VH10–VUSPIO nanoparticles in the plaque. Our work provides support for the further assessment of the use of VH10–VUSPIO nanoparticles as a promising imaging modality able to identify the early stages of atherosclerosis with regard to the pertinence of both the target and the antibody‐conjugated contrast agent used. Copyright

Identification of human scFVs targeting atherosclerotic lesions: Selection by single round in vivo phage-display

Our aim was to investigate by in vivo biopanning the lesions developed early in atherosclerosis and identify human antibodies that home to diseased regions. We have designed a two-step approach for a rapid isolation of human Monoclonal phage-display single-chain antibodies (MoPhabs) reactive with proteins found in lesions developed in an animal model of atherosclerosis. After a single round of in vivo biopanning, the MoPhabs were eluted from diseased sections of rabbit aorta identified by histology and NMR microscopy. MoPhabs expressed in situ were selected by subtractive colony filter screening for their capacity to recognize atherosclerotic but not normal aorta. MoPhabs selected by our method predominantly bind atherosclerotic lesions. Two of them, B3.3G and B3.GER, produced as scFv fragments, recognized an epitope present on the surface in early atherosclerotic lesions and within the intimal thickness in more complex plaques. These human MoPhabs homed to atherosclerotic lesions in ApoE-/- mice after in vivo injection. A protein of ∼56 kDa recognized by B3.3G was affinity-purified and identified by mass spectrometry analysis as vitronectin. This is the first time that single round in vivo biopanning has been used to select human antibodies as candidates for diagnostic imaging and for obtaining insight into targets displayed in atherosclerotic plaques.

Nanoparticles functionalised with an anti-platelet human antibody for in vivo detection of atherosclerotic plaque by magnetic resonance imaging

UNLABELLEDnAtherosclerosis is an inflammatory disease associated with the formation of atheroma plaques likely to rupture in which platelets are involved both in atherogenesis and atherothrombosis. The rupture is linked to the molecular composition of vulnerable plaques, causing acute cardiovascular events. In this study we propose an original targeted contrast agent for molecular imaging of atherosclerosis. Versatile USPIO (VUSPIO) nanoparticles, enhancing contrast in MR imaging, were functionalised with a recombinant human IgG4 antibody, rIgG4 TEG4, targeting human activated platelets. The maintenance of immunoreactivity of the targeted VUSPIO against platelets was confirmed in vitro by flow cytometry, transmission electronic and optical microscopy. In the atherosclerotic ApoE(-/-) mouse model, high-resolution ex vivo MRI demonstrated the selective binding of TEG4-VUSPIO on atheroma plaques. It is noteworthy that the rationale for targeting platelets within atherosclerotic lesions is highlighted by our targeted contrast agent using a human anti-αIIbβ3 antibody as a targeting moiety.nnnFROM THE CLINICAL EDITORnCurrent clinical assessment of atherosclerotic plagues is suboptimal. The authors in the article designed functionalized superparamagnetic iron oxide nanoparticles with TEG4, a recombinant human antibody, to target activated platelets. By using MRI, these nanoparticles can be utilized to study the process of atheroma pathogenesis.

Delayed immunologic thrombocytopenia induced by abciximab

Abciximab is an anti-GPIIb-IIIa drug widely used to prevent thrombotic complications during percutaneous coronary intervention. We now report on the immunologic origin of thrombocytopenia developing between 7 and 12 days after the onset of abciximab infusion. Antibodies directed against abciximabcoated platelets were located in 5 patients with delayed thrombocytopenia, just as they were present in a patient whose platelet count fell within a few hours after receiving the drug. Abciximab-dependent IgG antibody was revealed in serum using control platelets in the monoclonal antibody immobilization of platelet antigens assay (MAIPA) performed with SZ22, a MoAb to GPIIb. The presence of IgG antibodies specific for platelets sensitized with abciximab was confirmed by flow cytometry. They were not located in 13 patients receiving abciximab but whose platelet counts remained stable. For three patients, antibodies were transient and their presence related to the extent of the thrombocytopenia. Surprisingly, antibodycontaining plasma from three patients induced abciximabdependent activation and aggregation of normal platelets, a finding confirmed by electron microscopy. Immunogold labeling revealed that abciximab was associated with platelets in the aggregate, suggesting that its inhibitory effect was overcome by the platelet stimulation. In summary, these results show that abciximab-dependent thrombocytopenia can be delayed and potentially prothrombotic.

Thrombocytopenia after abciximab use results from different mechanisms.

Our study concerns thrombocytopenia in patients with acute ischaemic coronary artery disease receiving anti-platelet drugs to the aIIbb3 integrin (GPIIb/IIIa). We have screened for drug-dependent antibodies (DDAB) in 18 patients who suffered a fall of > 50% in platelet count (9 patients had a nadir of <50,000 platelets/microl) after receiving abciximab and related results to clinical outcome. Serum or plasma was screened for DDAB using (i) a direct ELISA against purified aIIbb3, aIIbb3-abciximab complexes or abciximab alone, (ii) control platelets and flow cytometry and (iii) monoclonal antibody immobilisation of platelet antigens. DDAB were found for 11 patients, with aIIbb3 ELISA the most sensitive test. Progressive platelet consumption linked with haemoglobin loss and/or use of intra-aortic balloon pumping, another potential cause of a fall in platelet count, was also evaluated. DDAB were identified that recognised aIIbb3 associated with abciximab and/or abciximab alone. Screening of both progressive and delayed thrombocytopenia (appearing after 5 to 11 days) suggested that antibodies against abciximab preceded those recognising neo-epitopes on aIIbb3, with a time-dependent broadening of antibody specificities. Higher titres were seen after second abciximab use. Five antibodies were platelet-activating. In conclusion, the mechanisms responsible for this complication of anti-aIIbb3 therapy are multiple and often associated with a complex immune response.

Solid Lipid Nanoparticles for Image-Guided Therapy of Atherosclerosis

Although the application of nanotechnologies to atherosclerosis remains a young field, novel strategies are needed to address this public health issue. In this context, the magnetic resonance imaging (MRI) approach has been gradually investigated in order to enable image-guided treatments. In this contribution, we report a new approach based on nucleoside-lipids allowing the synthesis of solid lipid nanoparticles (SLN) loaded with iron oxide particles and therapeutic agents. The insertion of nucleoside-lipids allows the formation of stable SLNs loaded with prostacycline (PGI2) able to inhibit platelet aggregation. The new SLNs feature better relaxivity properties in comparison to the clinically used contrast agent Feridex, indicating that SLNs are suitable for image-guided therapy.

Nanoparticle phagocytosis and cellular stress: involvement in cellular imaging and in gene therapy against glioma.

In gene therapy against glioma, targeting tumoral tissue is not an easy task. We used the tumor infiltrating property of microglia in this study. These cells are well adapted to this therapy since they can phagocyte nanoparticles and allow their visualization by MRI. Indeed, while many studies have used transfected microglia containing a suicide gene and other internalized nanoparticles to visualize microglia, none have combined both approaches during gene therapy. Microglia cells were transfected with the TK‐GFP gene under the control of the HSP70 promoter. First, the possible cellular stress induced by nanoparticle internalization was checked to avoid a non‐specific activation of the suicide gene. Then, MR images were obtained on tubes containing microglia loaded with superparamagnetic nanoparticles (VUSPIO) to characterize their MR properties, as well as their potential to track cells in vivo. VUSPIO were efficiently internalized by microglia, were found non‐toxic and their internalization did not induce any cellular stress. VUSPIO relaxivity r2 was 224u2009mM−1.s−1. Such results could generate a very high contrast between loaded and unloaded cells on T2‐weighted images. The intracellular presence of VUSPIO does not prevent suicide gene activity, since TK is expressed in vitro and functional in vivo. It allows MRI detection of gene modified macrophages during cell therapy strategies. Copyright

A case of profound and prolonged tirofiban-induced thrombocytopenia and its correction by intravenous immunoglobulin G

7 Tag CG, Schifflers MC, Mohnen M, Gressner AM, Weiskirchen R.Atypical melting curve resulting from genetic variation in the 3 un-translated region at position 20218 in the prothrombin gene analyzedwith the LightCycler factor II (prothrombin) G20210A assay. ClinChem 2005; 51: 1560–1.8 Wylenzek M, Geisen C, Stapenhorst L, Wielckens K, Klingler KR. Anovel point mutation in the 3 region of the prothrombin gene atposition 20221 in a Lebanese/Syrian family. Thromb Haemost 2001;85: 943–4.9 Balim Z, Kosova B, Falzon K, Bezz ina Wettinger S, Colak Y. Budd-Chiari syndrome in a patient heterozygous for the point mutationC20221T of the prothrombin gene. J Thromb Haemost 2003; 1: 852–3.10 Lyon E.Discovering rare variantsb yuseofmeltingtemperatureshiftsseen in melting curve analysis. Clin Chem 2005; 51: 1331–2.11 Hooper WC, Roberts S, Dowling N, Austin H, Lally C, Whitsett C.The prevalence of the prothrombin gene variant C20209T in African-Americans and Caucasians and lack of association with venousthromboembolism. Thromb Res 2006; 118: 767–8.12 Itakura H, Telen MJ, Hoppe CC, White DA, Zehnder JL. Char-acterization of a novel prothrombin variant, Prothrombin C20209T,as a modifier of thrombotic risk among African-Americans. J ThrombHaemost 2005; 3: 2357–9.13 DanckwardtS,HartmannK,KatzB,HentzeMW,LevyY,EicheleR,Deutsch V, Kulozik AE, Ben-Tal O. The prothrombin 20209 C–>Tmutation in Jewish-Moroccan Caucasians: molecular analysis of gain-of-function of 3 end processing. J Thromb Haemost 2006; 4: 1078–85.14 DanckwardtS,HartmannK,GehringNH,HentzeMW,KulozikAE.3 end processing of the prothrombin mRNA in thrombophilia. ActaHaematol 2006; 115: 192–7.15 Ceelie H, Spaargaren-Van Riel CC, Lyon E, Bertina RM, Vos HL.Functional analysis of two polymorphisms in the 3 -UTR of the hu-man prothrombin gene. J Thromb Haemost 2005; 3: 806–8.16 van der Putten HH, Spaargaren-van Riel CC, Bertina RM, Vos HL.Functional analysis of two prothrombin 3 -untranslated region var-iants: the C20209T variant, mainly f ound among African-Americans,and the C20209A variant. JThrombHaemost2006; 4: 2285–7; authorreply 2288–9.17 Danckwardt S, Hartmann K, Katz B, Ben-Tal O, Kulozik AE. Moreon: functional analysis of two prothrombin 3 UTR variants: theC20209T variant, mainly found among African-Americans, and theC20209A variant. J Thromb Haemost 2006; 4: 2288–9.18 Ceelie H, Bertina RM, van Hylckama Vlieg A, Rosendaal FR, VosHL. Polymorphisms in the prothro mbin gene and their associationwith plasma prothrombin levels. Thromb Haemost 2001; 85: 1066–70.19 Perez-Ceballos E, Corral J, Alberca I, Vaya A, Llamas P, Montes R,Gonzalez-Conejero R, Vicente V. Prothrombin A19911G andG20210A polymorphisms role in thrombosis. Br J Haematol 2002;118: 610–4.20 Danckwardt S, Gehring NH, Neu-Yilik G, Hundsdoerfer P, PforsichM, Frede U, Hentze MW, Kulozik AE. The prothrombin 3 end for-mation signal reveals a unique architecture that is sensitive to throm-bophilic gain-of-function mutations. Blood 2004; 104: 428–35.21 Gurgey A, Unal S, Okur H, Duru F, Gumruk F. ProthrombinG20210A mutation in Turkish children with thrombosis and the fre-quency of prothrombin C20209T. Pediatr Hematol Oncol 2005; 22:309–14.

By-passing large screening experiments using sequencing as a tool to identify scFv fragments targeting atherosclerotic lesions in a novel in vivo phage display selection.

Atherosclerosis is a chronic, progressive inflammatory disease that may develop into vulnerable lesions leading to thrombosis. To interrogate the molecular components involved in this process, single-chain variable fragments (scFvs) from a semi-synthetic human antibody library were selected on the lesions induced in a rabbit model of atherosclerosis after two rounds of in vivo phage display. Homing Phage-scFvs were isolated from (1) the injured endothelium, (2) the underlying lesional tissue and (3) the cells within the intima. Clones selected on the basis of their redundancy or the presence of key amino acids, as determined by comparing the distribution between the native and the selected libraries, were produced in soluble form, and seven scFvs were shown to specifically target the endothelial cell surface and inflamed intima-related regions of rabbit tissue sections by immunohistology approaches. The staining patterns differed depending on the scFv compartment of origin. This study demonstrates that large-scale scFv binding assays can be replaced by a sequence-based selection of best clones, paving the way for easier use of antibody libraries in in vivo biopanning experiments. Future investigations will be aimed at characterizing the scFv/target couples by mass spectrometry to set the stage for more accurate diagnostic of atherosclerosis and development of therapeutic strategies.

Rapid screening of purification strategies for the capture of a human recombinant F(ab )2 expressed in baculovirus-infected cells using a micro-plate approach and SELDI-MS

The development of a capture step of a human recombinant F(ab)(2) produced and expressed in baculovirus-infected cells was investigated by screening three mixed-mode chromatography sorbents (HEA HyperCel, PPA HyperCel and MEP HyperCel) and two ion exchangers (Q Ceramic HyperD F, S Ceramic HyperD F) sorbents using a 96-well plate format and SELDI-MS. HEA HyperCel gave the best separation performance therefore the conditions tested in micro-plate were transferred to laboratory scale chromatographic experiments, confirming that the recombinant F(ab)(2) was effectively captured on the mixed-mode sorbent without any pre-treatment of the crude extract with a 82% recovery and a 39-fold purification.